Why Genetic Diagnoses Take So Long for Kids
In this brief episode, host Catherine interviews the CEO of GeneDX about the stark delay—averaging five years—in diagnosing children with genetic diseases, despite the availability of rapid whole exome and genome sequencing that can deliver results in days. She explains that early diagnosis is crucial because you cannot treat what you cannot identify, and highlights GeneDX’s origins at the NIH and its mission to scale access to these technologies worldwide. The conversation underscores the transformative potential of gene editing and repair once diagnoses are made promptly, offering hope to save children from otherwise terminal conditions.
DDW Highlights: 14 April 2026
In this episode, Bruno Quinney highlights three major developments: the discovery of a new recessive neurodevelopmental disorder linked to mutations in the non‑coding gene RNU4‑2, a first‑in‑human trial of personalized CAR‑T cell therapies for hard‑to‑treat solid tumors in children, and...
Can a Transplant Cure Aging? | Catherine Baucom MD PhD
In this episode, Dr. Robert Lovekin talks with Dr. Catherine Baucom, chief medical officer of MitoSense, and veteran health expert Van about mitochondrial organelle transplantation—a novel therapy that injects healthy mitochondria from young donors into patients to repair damaged cells....
The Psychedelic Revolution
The episode explores the emerging field of psychedelic therapy, highlighting its potential to treat treatment‑resistant mental health conditions with a few supervised dosing sessions rather than daily medication. Guests Dr. Will Vanderveer and Keith Kurlander explain how the approach combines...
One Reporter’s Life-Altering Psychedelic Trip
In this episode of The Daily, host Natalie Kittrow discusses ibogaine—a powerful, illegal psychedelic—with veteran New York Times reporter Robert Draper, who recounts his recent ten‑hour treatment in Tijuana, Mexico. Draper explains ibogaine’s origins, its potential to trigger neuroplasticity and...
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
In this episode of Touching Base, the GEN editors discuss how AI agents are accelerating scientific discovery, highlighting startups like Latent Labs that can design therapeutic antibodies from a simple text prompt and LabOS, an extended‑reality platform that integrates AI,...
Why Diverse Thinking Builds Better AI | Biotech Leadership with Fernando Bardella
In this episode, host Steve Swan talks with global biotech executive Dr. Fernando Bardellá about how diverse cultural and disciplinary backgrounds drive better AI and technology strategies in life sciences. Bardellá shares insights from moving from France to Boston, highlighting...
Intercepting Cancer When DNA Surveillance Fails
In this episode, Daniel Levine talks with Marina Udier, CEO of Newscom, about the company’s innovative cancer‑interception strategy that targets tumors arising from microsatellite instability (MSI) and deficient DNA mismatch repair, such as those seen in Lynch syndrome. Udier explains...
DDW Highlights: 7 April 2026
In this episode, Bruno Quinney highlights several breakthrough developments in drug discovery: the FDA’s accelerated approval of Avlaya, the first brain‑penetrant biologic for Hunter syndrome; Eli Lilly’s $2 billion acquisition of Centessa Pharmaceuticals to expand its orexin‑based sleep‑wake therapies; Mount Sinai’s AI‑powered...
The Longevity Nerve: The Missing Link in Stress, Aging & Brain Health | Elisabetta Burchi MD
In this episode, Dr. Elisabetta Burchi explains how the vagus nerve serves as a central hub linking the brain to the heart, gut, immune system, and overall longevity. She outlines the anatomy and function of the vagus within the parasympathetic...
Decentralized Trials That Scale Globally Without Compliance Risks - with Emma Vitalini of Amgen
In this episode, Emma Vitalini, Head of Global Digital Health Technology Innovation at Amgen, discusses how AI and decentralized trial technologies are transforming patient recruitment, screening, and global trial accessibility. She explains that AI can rapidly parse unstructured genomic and...
Dr Sorcha O'Connor: The PsilOCD Study Investigating Low-Dose Psilocybin for OCD (#532)
In this episode, host Stuart Ralph talks with Dr. Saoirse O'Connor, a neuroscientist who led the PsilOCD study—the first controlled European trial of low‑dose psilocybin for obsessive‑compulsive disorder. The conversation covers the science of psilocybin, the study design (a 10 mg...
How Drug Discovery Is Tackling Global Health Challenges
In this DDW podcast episode, host Bruno Quinney discusses two recent DDW articles: one on the urgent need to combat antimicrobial resistance (AMR) with insights from Professor Janet Hemingway, and another on the rapid expansion of mRNA therapeutics. Hemingway highlights...
28 Months Later: FDA Still Hasn't Revealed Rick Bright and Janet Woodcock's Communications
The episode delves into the controversy surrounding the FDA’s handling of hydroxychloroquine during the COVID‑19 pandemic, focusing on whistleblower Dr. Rick Bright’s claims that Dr. Janet Woodcock pressured him to pursue an Emergency Use Authorization (EUA) rather than an expanded‑access protocol....
The War on Peptides — Why Retatrutide Is at the Center
In this episode of Business Game Changers, host Sarah Westall and Dr. Diane Kayser discuss the rapidly evolving peptide market, focusing on the upcoming weight‑loss peptide retatrutide (also called Reditrutide). They explain how big‑pharma is moving to control peptide supplements,...
